- Home
- RYOJ vs OTLK Comparison
RYOJ vs OTLK Comparison
Compare RYOJ & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYOJ | OTLK |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 38.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RYOJ | OTLK |
|---|---|---|
| Price | $2.27 | $0.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 28.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,726.70 |
| Revenue Next Year | N/A | $80.34 |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $0.38 |
| 52 Week High | $11.43 | $3.39 |
Technical Indicators
Market Signals| Indicator | RYOJ | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 36.48 |
| Support Level | $1.84 | $0.39 |
| Resistance Level | $2.39 | $0.46 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 10.00 | 16.93 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.